Skip Navigation


European Heart Journal Advance Access originally published online on April 28, 2005
European Heart Journal 2005 26(14):1369-1378; doi:10.1093/eurheartj/ehi225
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/14/1369    most recent
ehi225v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Daly, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daly, C. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy

Caroline A. Daly1, Kim M. Fox1,*, Willem J. Remme2, Michel E. Bertrand3, Roberto Ferrari4, Maarten L. Simoons5 on behalf of the EUROPA investigators

1Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
2Sticares Cardiovascular Research Institute, Rotterdam–Rhoon, The Netherlands
3Cardiology Hospital, Lille, France
4Hospital Santa Anna, Ferrara, Italy
5ThoraxCenter Erasmus Medical Centre, Rotterdam, The Netherlands

Received 13 August 2004; revised 31 January 2005; accepted 17 February 2005; online publish-ahead-of-print 28 April 2005.

* Corresponding author. Tel: +44 20 7351 8626; fax: +44 20 7351 8629. E-mail address: k.fox{at}rbh.nthames.nhs.uk

See page 1347 for the editorial comment on this article (doi:10.1093/eurheartj/ehi308)

Aims The aim of this study was to assess the effect of the angiotensin converting enzyme inhibitor perindopril on cardiovascular events in diabetic patients with coronary artery disease.

Methods and results A total of 1502 diabetic patients with known coronary artery disease and without heart failure of 12 218 overall in the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery (EUROPA) disease were randomized in a double-blinded manner to perindopril 8 mg once daily or placebo. Follow-up was for a median of 4.3 years. The primary end point was cardiovascular death, non-fatal myocardial infarction, and resuscitated cardiac arrest. Perindopril treatment was associated with a non-significant reduction in the primary endpoint in the diabetic population, 12.6 vs. 15.5%, relative risk reduction 19% [(95% CI, –7 to 38%), P=0.13]. This was of similar relative magnitude to the 20% risk reduction observed in the main EUROPA population.

Conclusion Perindopril tends to reduce major cardiovascular events in diabetic patients with coronary disease in addition to other preventive treatments and the trend towards reduction was of a similar relative magnitude to that observed the general population with coronary artery disease.

Key Words: Randomized controlled trial • ACE inhibitor • Diabetes mellitus • Stable coronary disease • Secondary prevention


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE
Subodh Verma, Lawrence A. Leiter, Eva M. Lonn, and Martin H. Strauss
EHJ 2005 26: 1347-1349. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
M. Tendera
Introduction
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E1 - E1.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
K. Fox
Contribution of perindopril to cardiology: 20 years of success
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E10 - E19.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
R. Donnelly and G. Manning
Review: Angiotensin-converting enzyme inhibitors and coronary heart disease prevention
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2007; 8(1): 13 - 22.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
C. Ceconi, K. M. Fox, W. J. Remme, M. L. Simoons, M. Bertrand, G. Parrinello, C. Kluft, A. Blann, D. Cokkinos, and R. Ferrari
ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT
Cardiovasc Res, January 1, 2007; 73(1): 237 - 246.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
M. Kirby
Heart failure and diabetes in primary care
The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 220 - 228.
[Abstract] [PDF]

Home page
 Diabetes Spectr.Home page
B. Stults and R. E. Jones
Management of Hypertension in Diabetes
Diabetes Spectr, January 1, 2006; 19(1): 25 - 31.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. Donnelly
Review: Managing cardiovascular risk in patients with diabetes
The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 325 - 329.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
S. Verma, L. A. Leiter, E. M. Lonn, and M. H. Strauss
Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE
Eur. Heart J., July 2, 2005; 26(14): 1347 - 1349.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.